First US Deal Signals Physitrack's Enterprise Pivot Is Working

Physitrack (PTRK) announced a new commercial agreement with a New York state-based academic medical center, with a total contract value of $ 100,556 and annual recurring revenue of $31,897, covering 190 clinician users. Revenue recognition is expected to commence in Q2 2026, with the press release flagging subsequent phases that may include expanded scope and additional licenses. The deal itself is not material to our projections. At roughly EUR 29,000 in ARR, it represents less than 0.3% of Lifecare's estimated annual revenue base of EUR 10-11m. What matters is the signal, not the size.

Americas Expansion: This is the first concrete US enterprise deal we have seen since Physitrack increased its Americas focus. The company has been building out a New York office, and CEO Henrik Molin's comments frame this explicitly as a kickoff:

Academic medical centers are credibility-conferring customers in the US healthcare system; they serve as reference accounts that open doors to other hospital networks. Landing one, even at modest initial scale, validates that the Physitrack platform can win institutional business in the world's largest healthcare market.

Enterprise Push: The broader pattern is worth noting. This is the third institutional deal Physitrack has announced in March alone, following two agreements with Swiss hospital groups with a combined contract value of approximately CHF 300,000. All three are Lifecare segment, all enterprise-scale (150-190 users), and all include language about expansion phases. The go-to-market is clearly evolving from individual practitioner subscriptions toward higher-value institutional sales with longer contracts and built-in upsell mechanics. This shift, if sustained, supports our base case assumption of 9% Lifecare revenue CAGR through 2027.

Outperform: The market continues to ignore Physitrack's progress, which is not uncommon in the current environment for a microcap in transition. We, however, see a company that is not in a turnaround, but one that has already turned around. The question now is pipeline depth. One US deal is a start, not a trend, and we will be watching Q2 2026 earnings closely for commentary on Americas commercial traction and whether additional US logos follow. We rate Physitrack as Outperform with a target of SEK 22-25.

Read our latest deep-dive on PTRK here.

Disclaimer

This analysis represents the independent views of Lind Research and is based on publicly available information believed to be reliable, but no warranty is given as to its accuracy or completeness. Nothing herein is investment advice or a recommendation. We publish openly, and companies do not influence our conclusions. Lind Research may hold positions in securities discussed.

Analyst owns shares? Yes

Lind Research